M.Pharm in Pharm. Chemistry, Pharm. Analysis, Quality Assurance. Kota College of Pharmacy (KCP) was established by Oasis educational society, Jaipur in 2004 at SP-1, RIICO Industrial Area, Ranpur, Jhalawar Road, Kota (Raj.)
Post Graduate in Pharmacology (M.Pharm/M.S Pharm). OR Post Graduate (M.Sc) in Biomedical Sciences, Life Sciences, Physiology, Biochemistry & Biotechnaology
A Basic degree in Pharmacy (B.Pharm.). Registration as a pharmacist under the Pharmacy Act, 1948, as amended from time to time, including any succeeding enactments.
Four years Bachelors degree in Natural or Agricultural Sciences or Masters degree in Natural or Agricultural Sciences/ BVSc / B.Pharm or Bachelors degree in Engineering or Technology or Medicine or from a recognized University or equivalent
Applications are invited online for filling up of position on a purely temporary basis, in the prescribed proforma. The details of the Sponsored Project under which engagement is proposed to be made is as under.
Post : Project Associate-I
Title of Project : Moisture Triggered Starch/Nano Cellulose Based Controlled Release System For The Delivery Of Herbicides In Rainfed Ecosystems Name of Sponsoring Agency : ANRF
First-class postgraduate degree in Biotechnology. PhD in biophysics / biochemistry with at least two first-authored research publications in a reputed peer- reviewed journal.
Post Graduate Degree in Basic Science OR Graduate / Post Graduate Degree in Professional Course selected through a process described through National Eligibility Tests - CSIR- UGC NET including lectureship (Assistant Professorship) or GATE
Bachelor degree in clinical research Or Social sciences or Biotechnology. Experience in working projects / programs. Demonstrated ability to liaison with different and multiple organizations
Fresenius Kabi India is a global healthcare company MNC that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition.
Researchers at University of Southampton have uncovered a key mechanism that allows lung cancer cells to become more aggressive and resistant to treatment by switching back to an earlier developmental state.
Researchers from Medical University of Vienna have identified a major mechanism that allows breast cancer tumours to escape the body’s immune system, opening the door for more effective immunotherapy treatments in the future.
Pharma major AstraZeneca has received an extension in the US FDA review timeline for its investigational breast cancer therapy camizestrant, a next-generation oral selective estrogen receptor degrader (SERD) being evaluated for HR-positive, HER2-negative advanced breast cancer with ESR1 mutations.
AstraZeneca and Daiichi Sankyo have announced that the U.S. Food and Drug Administration (FDA) has approved DATROWAY (datopotamab deruxtecan-dlnk) for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. The approval makes DATROWAY the first TROP2-directed antibody-drug conjugate (ADC) approved in the United States for first-line treatment in this patient population.